对比分析减肥产品排行榜首位来利奥利司他与安慰剂对患有轻到中度高胆固醇血症的肥胖患者的疗效和安全性

对比分析减肥产品排行榜首位来利奥利司他与安慰剂对患有轻到中度高胆固醇血症的肥胖患者的疗效和安全性，一项随机双盲研究作者：JOÃOJÁCOMEDECASTRO,TERESADIAS,PAULACHAMBEL,MANUELACARVALHEIRO,LUÍSGARDETTECORREIA,LILIANAGUERREIRO,OLINDAMARQUES,JOSÉLUÍSMEDINA,EMANOBRE,JOSÉSILVANUNES,MARIACARLOSPEREIRA,JORGEPOLÓNIA,JORGEPORTUGAL,ANABELARAIMUNDO,ALMEIDARUAS,PEDROMARQUESDASILVA,CARLOSVASCONCELOS,JOSÉLIMAREIS,ALBERTOGALVÃOTELES.作者单位：JOÃOJÁCOMEDECASTRO,PAULACHAMBEL:内分泌科,葡萄牙军事医院;TERESADIAS,EMANOBRE,ALBERTOGALVÃOTELES:内分泌科,葡萄牙圣玛利亚医院;MANUELACARVALHEIRO,ALMEIDARUAS:S.内分泌科,葡萄牙HUC医院;LUÍSGARDETTECORREIA,JOSÉSILVANUNES:内分泌科,葡萄牙库里卡尔拉医院;LILIANAGUERREIRO,CARLOSVASCONCELOS:内分泌科,葡萄牙莫尼斯医院;OLINDAMARQUES:内分泌科,葡萄牙圣马尔克斯医院;JOSÉLUÍSMEDINA,JOSÉLIMAREIS:内分泌科,葡萄牙S.Joao医院;MARIACARLOSPEREIRA,JORGEPORTUGAL:内分泌科,葡萄牙加西亚奥尔塔医院;JORGEPOLÓNIA:药理学部,葡萄牙S.joao医院;ANABELARAIMUNDO,PEDROMARQUESDASILVA,：医学部,葡萄牙圣玛尔塔医院。【摘自】葡萄牙心血管杂志，2009年第28期12刊1361-1374。【摘要】背景：肥胖是一个慢性病，同时还会增加患上糖尿病、高血压、血脂异常和冠心病等多种疾病的几率。目地：通过6个月的治疗，分别评估减肥产品排行榜首位来利奥利司他和安慰剂对伴高脂血症的肥胖患者在减重和改善血脂方面的疗效。方法：在6个月内，采用多通道(葡萄牙内10个研究中心)，双盲，平行，安慰剂对照等试验方法，对166个年龄在18~65岁之间、BMI≥27kg/m2、低密度脂蛋白＞155mg/dl的受试者进行研究，把他们随机安排到低卡路里饮食并加上减肥产品排行榜首位来利奥利司他或安慰剂进行治疗。排除的检查标准包括甘油三酯＞400mg/dl，严重的心血管疾病，不受控制的高血压，需要药物治疗的1型或2型糖尿病，以及胃肠道和胰腺疾病。结果：减肥产品排行榜首位来利奥利司他组体重值与起始的平均偏差为5.9%(5.6kg)，安慰剂组为2.3%(2.2kg)。在减肥产品排行榜首位来利奥利司他组中，有49%的患者成功减掉了5%-10%的体重，其中有8.8%的人减掉了10%以上的体重。同时，减肥产品排行榜首位来利奥利司他组在降低总胆固醇和低密度脂蛋白上有着显著的影响，两组均对高密度脂蛋白有着近似的影响。在胃肠道副作用方面，减肥产品排行榜首位来利奥利司他组轻微的高于安慰剂组，其中有7名患者停止用药。结论：服用减肥产品排行榜首位来利奥利司他及低热量饮食6个月后可显著降低体重，BMI和血脂参数，有效改善血脂和高血糖症。【文献原文】Arandomizeddouble-blindstudycomparingtheefficacyandsafetyoforlistatversus,placeboinobesepatientswithmildtomoderatehypercholesterolemiaAuthor:JOÃOJÁCOMEDECASTRO,TERESADIAS,PAULACHAMBEL,MANUELACARVALHEIRO,LUÍSGARDETTECORREIA,LILIANAGUERREIRO,OLINDAMARQUES,JOSÉLUÍSMEDINA,EMANOBRE,JOSÉSILVANUNES,MARIACARLOSPEREIRA,JORGEPOLÓNIA,JORGEPORTUGAL,ANABELARAIMUNDO,ALMEIDARUAS,PEDROMARQUESDASILVA,CARLOSVASCONCELOS,JOSÉLIMAREIS,ALBERTOGALVÃOTELES.Authorinformation：JOÃOJÁCOMEDECASTRO,PAULACHAMBEL:S.Endocrinologia,HospitalMilitarPrincipal;TERESADIAS,EMANOBRE,ALBERTOGALVÃOTELES:S.Endocrinologia,HospitalSantaMaria;MANUELACARVALHEIRO,ALMEIDARUAS:S.Endocrinologia,HUC;LUÍSGARDETTECORREIA,JOSÉSILVANUNES:S.Endocrinologia,HospitalCurryCabral;LILIANAGUERREIRO,CARLOSVASCONCELOS:S.Endocrinologia,HospitalEgasMoniz;OLINDAMARQUES:S.Endocrinologia,HospitalSaoMarcos;JOSÉLUÍSMEDINA,JOSÉLIMAREIS:S.Endocrinologia,HospitalS.Joao;MARIACARLOSPEREIRA,JORGEPORTUGAL:S.Endocrinologia,HospitalGarciadeOrta;JORGEPOLÓNIA:UnidadedeFarmacologia,HospitalS.joao;ANABELARAIMUNDO,PEDROMARQUESDASILVA,：S.Medicina,HospitalSantaMarta.QuoteFrom:RevistaPortuguesadeCardiologia(2009);28(12):1361-1374.【ABSTRACT】Introduction:Obesityisachronicdiseaseandaserioushealthproblemthatleadstoincreasedprevalenceofdiabetes,hypertension,dyslipidemiaandgallbladderdisease.Objective:Toevaluatetheefficacyoforlistatforweightlossandimprovedlipidprofilecomparedtoplaceboinobesepatientswithhypercholesterolemia,treatedoveraperiodof6months.Methodology:Ina6-month,multicenter(10centersinPortugal),double-blind,parallel,placebo-controlledstudy,166patients,aged18-65years,bodymassindex(BMI)≥27kg/m2,LDLcholesterol155mg/dl,wererandomizedtoareducedcaloriediet(600kcal/daydeficit)plusorlistatthreetimesadayorplacebo.Exclusioncriteriaincludedtriglycerides400mg/dl,severecardiovasculardisease,uncontrolledhypertension,type1or2diabetesunderpharmacologicaltreatment,andgastrointestinalorpancreaticdisease.Results：Themeandifferenceinweightfrombaselinewas5.9%(5.6kg)intheorlistatgroupvs.2.3%(2.2kg)intheplacebogroup.Intheorlistatgroup49%ofpatientsachieved5-10%weightlossand8.8%achieved10%.TheorlistatgroupshowedasignificantreductionintotalandLDLcholesterol,withsimilarchangesforHDLinbothtreatmentgroups.Thefrequencyofgastrointestinaladverseeventswasslightlyhigherintheorlistatgroupthanintheplacebogroup,leadingtodiscontinuationin7patients.Conclusions：Treatmentwithorlistatplusareducedcaloriedietfor6monthsachievedsignificantreductionsinweight,BMIandlipidparameters.